FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis
出版年份 2020 全文链接
标题
FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis
作者
关键词
-
出版物
Cell Death & Disease
Volume 11, Issue 10, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-10-13
DOI
10.1038/s41419-020-03053-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib
- (2020) Chunzhan Wang et al. PHARMACOLOGICAL RESEARCH
- DNA methyltransferase mediates the hypermethylation of the microRNA 34a promoter and enhances the resistance of patient-derived pancreatic cancer cells to molecular targeting agents
- (2020) Yan Ma et al. PHARMACOLOGICAL RESEARCH
- A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes
- (2019) Kan Yonemori et al. EUROPEAN JOURNAL OF CANCER
- GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner
- (2019) Fen Lin et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Cortisol-induced SRSF3 expression promotes GR splicing, RACK1 expression and breast cancer cells migration
- (2019) Erica Buoso et al. PHARMACOLOGICAL RESEARCH
- Menopausal hormone therapy and 20-year breast cancer mortality
- (2019) Valerie Beral et al. LANCET
- SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity
- (2019) Fan Yin et al. Cell Death & Disease
- Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC‐MS/MS
- (2019) Stefanie Krens et al. BIOMEDICAL CHROMATOGRAPHY
- TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR
- (2019) Ella Bhagyaraj et al. CELL CYCLE
- Targeted Therapies for Triple-Negative Breast Cancer
- (2019) Tomas G. Lyons CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
- (2019) Bradley A. McGregor et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine
- (2019) Paola Cavalcante et al. PHARMACOLOGICAL RESEARCH
- Triple negative breast cancer: A thorough review of biomarkers
- (2019) Jesse Lopes da Silva et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The role of MicroRNAs on endoplasmic reticulum stress in myocardial ischemia and cardiac hypertrophy
- (2019) Navid Omidkhoda et al. PHARMACOLOGICAL RESEARCH
- TLR5: A prognostic and monitoring indicator for triple-negative breast cancer
- (2019) Dai Shi et al. Cell Death & Disease
- Xenobiotic receptors in mediating the effect of sepsis on drug metabolism
- (2019) Chuanzhu Lv et al. Acta Pharmaceutica Sinica B
- Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma
- (2018) Fan Feng et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Transcriptional Regulation of the Warburg Effect in Cancer by SIX1
- (2018) Ling Li et al. CANCER CELL
- The Roles of Xenobiotic Receptors: Beyond Chemical Disposition
- (2018) Bryan Mackowiak et al. DRUG METABOLISM AND DISPOSITION
- Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
- (2018) Min Yuen Teo et al. JOURNAL OF CLINICAL ONCOLOGY
- Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases
- (2018) Neal Shah et al. PHARMACOLOGICAL RESEARCH
- A new apatinib microcrystal formulation enhances the effect of radiofrequency ablation treatment on hepatocellular carcinoma
- (2018) Hui Xie et al. OncoTargets and Therapy
- Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells
- (2018) Yingshi Zhang et al. Cell Death & Disease
- ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR
- (2018) Zhiyi Shao et al. PHARMACOLOGICAL RESEARCH
- MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor
- (2018) Jiaqi Li et al. OncoTargets and Therapy
- Aminophenols increase proliferation of thyroid tumor cells by inducing the transcription factor activity of estrogen receptor α
- (2018) Lin Wang et al. BIOMEDICINE & PHARMACOTHERAPY
- Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells
- (2018) Yanli Wang et al. OncoTargets and Therapy
- Procaspase-3-activating compound 1 stabilizes hypoxia-inducible factor 1α and induces DNA damage by sequestering ferrous iron
- (2018) Feifei Li et al. Cell Death & Disease
- Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition
- (2017) Stephanie Lheureux et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- WX-132-18B, a novel microtubule inhibitor, exhibits promising anti-tumor effects
- (2017) Fang Guan et al. Oncotarget
- Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents
- (2016) Hui Jia et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed
- (2016) Wendie D. den Brok et al. BREAST CANCER RESEARCH AND TREATMENT
- Cross-talk between EPAS-1/HIF-2α and PXR signaling pathway regulates multi-drug resistance of stomach cancer cell
- (2016) Jiuda Zhao et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer
- (2016) N. A. Jabbour-Leung et al. MOLECULAR CANCER THERAPEUTICS
- Pokemon (FBI-1) interacts with Smad4 to repress TGF-β-induced transcriptional responses
- (2015) Yutao Yang et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- The RNA-binding protein RBPMS1 represses AP-1 signaling and regulates breast cancer cell proliferation and migration
- (2015) Jie Fu et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K
- (2014) J. C. Liu et al. EMBO Molecular Medicine
- The transcription factor FBI-1 inhibits SAM68-mediated BCL-X alternative splicing and apoptosis
- (2014) P. Bielli et al. EMBO REPORTS
- Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
- (2014) M. Bonotto et al. ONCOLOGIST
- FBI-1 Enhances ETS-1 Signaling Activity and Promotes Proliferation of Human Colorectal Carcinoma Cells
- (2014) Min Zhu et al. PLoS One
- LINE-1 ORF-1p functions as a novel HGF/ETS-1 signaling pathway co-activator and promotes the growth of MDA-MB-231 cell
- (2013) Qian Yang et al. CELLULAR SIGNALLING
- The proto-oncoprotein FBI-1 interacts with MBD3 to recruit the Mi-2/NuRD-HDAC complex and BCoR and to silence p21WAF/CDKN1A by DNA methylation
- (2013) Won-Il Choi et al. NUCLEIC ACIDS RESEARCH
- LINE-1 ORF-1p functions as a novel androgen receptor co-activator and promotes the growth of human prostatic carcinoma cells
- (2012) Yinying Lu et al. CELLULAR SIGNALLING
- The Silencing of Pokemon Attenuates the Proliferation of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Inhibiting the PI3K/Akt Pathway
- (2012) Chan-Chan Lin et al. PLoS One
- FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo
- (2011) Feng Fang et al. CANCER
- Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers
- (2011) LiLi Jiang et al. Molecular Cancer
- Expression of leukemia/lymphoma-related factor (LRF/POKEMON) in human breast carcinoma and other cancers
- (2010) Anshu Aggarwal et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Proto-oncogene FBI-1 Represses Transcription ofp21CIP1by Inhibition of Transcription Activation by p53 and Sp1
- (2009) Won-Il Choi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Proto-oncogene FBI-1 (Pokemon/ZBTB7A) Represses Transcription of the Tumor SuppressorRbGene via Binding Competition with Sp1 and Recruitment of Co-repressors
- (2008) Bu-Nam Jeon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started